THX Pharma Publishes Shareholder Letter
THX Pharma (Theranexus) announced on January 8 the online publication of its shareholder letter, according to a press release issued Wednesday evening.
Publication Details
The Lyon-based biopharmaceutical group, specializing in the treatment of rare neurological diseases, indicated that it has published its letter intended for shareholders. The document is available on the company's website, in the section dedicated to financial documents. The company also invites its shareholders to register to receive all its communications.
Current Pharmaceutical Developments
According to the press release, THX Pharma is currently developing two drugs. The first, TX01, is soon to be marketed in Europe by Exeltis, as well as in the United States, Canada, and Australia, for the treatment of Niemann-Pick disease type C and Gaucher's disease. The second, Batten-1, targets the juvenile form of Batten disease. The company also has a platform for antisense oligonucleotides developed in collaboration with research laboratories, still within the field of rare neurological diseases.
Market Presence and Information Integrity
THX Pharma, the commercial name of Theranexus, is listed on the Euronext Growth market in Paris under the mnemonic ALTHX. The press release specifies that the content distributed benefits from a system to combat the dissemination of false information certified by Finance Innovation. No financial figures or strategic direction was communicated in the announcement.
